Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need.
The Sentinel Oncology portfolio includes a lead programme that has been licensed to Oncothyreon Inc. and a second programme which is at the candidate drug phase. We are further developing a suite of novel small molecules designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour.
Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.
If you would like to speak to someone from Sentinel Oncology, please get in touch.